Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] KEYNOTE-006: a success in melanoma, but a long way to go

A breakthrough in cancer therapy was achieved by the introduction of immune checkpoint inhibition, starting with the US Food and Drug Administration approval of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)-specific antibody ipilimumab in 2011.1,2 Since then, clinical experience indicates that only around 20% of patients with late-stage melanoma experience durable responses with ipilimumab, but can pay a high price in terms of adverse events, because ipilimumab has been associated with autoimmune reactions like colitis that can require treatment discontinuation.